Table 2. Data comparison of patients with baseline, interim and end-of-treatment PET/CT.
| Characteristics | SUVmax |
p | WBMTV |
p | WBTLG |
p | I-PET |
p | E-PET |
p | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ≤15.1 n = 26 | >15.1 n = 21 | ≤16.1 n = 31 | >16.1 n = 16 | ≤44.7 n = 21 | >44.7 n = 26 | Neg n = 19 | Pos n = 15 | Neg n = 19 | Pos n = 9 | ||||||
| Sex (M/F) | 16/10 | 11/10 | 0.528 | 15/16 | 12/4 | 0.080 | 10/11 | 17/9 | 0.221 | 10/9 | 10/5 | 0.495 | 12/7 | 4/5 | 0.432 |
| Age (≤60/>60) | 23/3 | 20/1 | 0.763 | 28/3 | 15/1 | 1.000 | 19/2 | 24/2 | 1.000 | 18/1 | 12/3 | 0.299 | 17/2 | 8/1 | 1.000 |
| B symptoms (No/Yes) | 14/12 | 6/15 | 0.081 | 15/16 | 5/11 | 0.260 | 13/8 | 7/19 | 0.016 | 7/12 | 6/9 | 1.000 | 7/12 | 4/5 | 1.000 |
| ECOG (<2/≥2) | 18/8 | 16/5 | 0.596 | 23/8 | 11/5 | 0.959 | 18/3 | 16/10 | 0.065 | 17/2 | 11/4 | 0.370 | 13/6 | 5/4 | 0.677 |
| LDH level (≤245/>245) | 19/7 | 7/14 | 0.006 | 20/11 | 6/10 | 0.078 | 14/7 | 12/14 | 0.160 | 12/7 | 7/8 | 0.489 | 10/9 | 3/6 | 0.435 |
| IPI score (0–1/2–5) | 19/7 | 15/6 | 0.900 | 26/5 | 8/8 | 0.034 | 20/1 | 14/12 | 0.002 | 15/4 | 12/3 | 1.000 | 12/7 | 6/3 | 1.000 |
| KPI score (0–2/3–4) | 22/4 | 10/11 | 0.007 | 24/7 | 8/8 | 0.056 | 18/3 | 14/12 | 0.020 | 15/4 | 7/8 | 0.075 | 12/7 | 4/5 | 0.432 |
| Ann Arbor Stage (I/II/III/IV) | 19/7 | 10/11 | 0.074 | 24/7 | 6/10 | 0.007 | 17/4 | 13/13 | 0.028 | 13/6 | 10/5 | 1.000 | 12/7 | 4/5 | 0.432 |
| Lesions (UAT/NUAT) | 23/3 | 14/7 | 0.145 | 29/2 | 8/8 | 0.002 | 20/1 | 17/9 | 0.033 | 16/3 | 10/5 | 0.417 | 4/15 | 5/4 | 0.097 |
ECOG, Eastern Cooperative Oncology Group; IPI, International Prognostic Index; KPI, Korean prognostic index; UAT, upper aerodigestive tract; NUAT, non-upper aerodigestive tract; SUVmax, maximum standardized uptake value; WBMTV, whole-body metabolic tumour volume; WBTLG, whole-body total lesion glycolysis; I-PET, interim PET/CT; E-PET, end-of-treatment PET/CT; Neg, negative; Pos, positive.